• 1. Excited state dynamics of symmetric and asymmetric Cr3(dpa)4Cl2 measured using femtosecond transient absorption spectroscopy?
  Chao-Han Cheng,Wen-Zhen Wang,Shie-Ming Peng,I-Chia Chen Phys. Chem. Chem. Phys., 2017,19, 25471-25477
• 2. Exchanged ligands on the surface of a giant cluster: [(MoO3)176(H2O)63(CH3OH)17Hn](32 – n)–
  Chem. Commun., 1998, 1501-1502
• 3. Emerging investigator series: bacteriophages as nano engineering tools for quality monitoring and pathogen detection in water and wastewater
  Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389
• 4. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126
• 5. Excimer and exciplex formation in a pair of bright phosphorescent isomers constructed from Cu3(pyrazolate)3 and Cu3I3 coordination luminophores?
  Shun-Ze Zhan,Mian Li,Xiao-Ping Zhou,Dan Li,Seik Weng Ng RSC Adv., 2011,1, 1457-1459

Methyl 3-azabicyclo[3.3.1]nonane-9-carboxylate (CAS No. 1544665-43-1): A Comprehensive Overview

Methyl 3-azabicyclo[3.3.1]nonane-9-carboxylate (CAS No. 1544665-43-1) is a specialized organic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal research. This compound, characterized by its unique bicyclic structure and azacycloalkane moiety, presents a promising scaffold for the development of novel therapeutic agents. Its molecular architecture, featuring a nine-membered azabicycloalkane ring system, makes it an intriguing candidate for further exploration in drug discovery programs.

The chemical structure of methyl 3-azabicyclo[3.3.1]nonane-9-carboxylate is defined by a fused bicyclic system consisting of three rings: a cyclopropane ring, a cyclopentane ring, and a heptane ring, with an azide functional group at the third position. This intricate arrangement imparts distinct stereochemical and electronic properties to the molecule, which are critical for its potential biological activity. The presence of the ester group at the terminal position further enhances its versatility as a synthetic intermediate.

In recent years, there has been growing interest in the development of heterocyclic compounds for their diverse pharmacological properties. The bicyclic framework of methyl 3-azabicyclo[3.3.1]nonane-9-carboxylate aligns well with this trend, as it offers a privileged scaffold that can be modified to target various biological pathways. Researchers have been particularly intrigued by its potential applications in the treatment of neurological disorders, given the structural similarity to known bioactive molecules that interact with central nervous system receptors.

One of the most compelling aspects of methyl 3-azabicyclo[3.3.1]nonane-9-carboxylate is its synthetic accessibility. The compound can be readily prepared through multi-step organic transformations, including cyclization reactions and esterification processes. These synthetic routes have been optimized to ensure high yields and purity, making it suitable for both laboratory-scale investigations and industrial production.

The pharmacological profile of methyl 3-azabicyclo[3.3.1]nonane-9-carboxylate has been extensively studied in preclinical models. Initial experiments have demonstrated its ability to modulate certain neurotransmitter systems, suggesting potential therapeutic benefits in conditions such as anxiety and depression. Additionally, its structural features have been shown to enhance binding affinity to specific protein targets, which could lead to the development of more potent and selective drug candidates.

Recent advancements in computational chemistry have further facilitated the investigation of methyl 3-azabicyclo[3.3.1]nonane-9-carboxylate. Molecular docking studies have revealed promising interactions with enzymes and receptors involved in disease pathways, providing valuable insights into its mechanism of action. These computational approaches complement traditional experimental techniques, enabling researchers to design more targeted modifications and optimize lead compounds efficiently.

The biodegradability and environmental impact of methyl 3-azabicyclo[3.3.1]nonane-9-carboxylate are also important considerations in its development as a pharmaceutical agent. Preliminary assessments indicate that the compound exhibits moderate biodegradability under aerobic conditions, suggesting that it can be safely handled and disposed of without significant environmental harm.

In conclusion, methyl 3-azabicyclo[3.3.1]nonane-9-carboxylate (CAS No. 1544665-43-1) represents a fascinating compound with significant potential in pharmaceutical research and drug development. Its unique structural features, synthetic accessibility, and promising pharmacological properties make it an attractive candidate for further investigation.

• 1246167-37-2(methyl decahydroisoquinoline-5-carboxylate)
• 1221825-06-4(Methyl decahydroisoquinoline-8-carboxylate)
• 1400864-80-3(rac-methyl (3R,4R)-3-methylpiperidine-4-carboxylate)
• 133567-11-0(methyl trans-3-methylpiperidine-4-carboxylate)
• 775538-49-3(6-Isoquinolinecarboxylicacid, decahydro-2-methyl-, methyl ester, (4aR,6R,8aS)-rel-)
• 802010-81-7(5-Isoquinolinecarboxylicacid, 2-ethyldecahydro-, methyl ester)
• 133567-09-6(methyl cis-3-methylpiperidine-4-carboxylate)
• 104654-01-5(7-Isoquinolinecarboxylic acid, decahydro-, methyl ester)
• 845909-33-3(methyl 3-methylpiperidine-4-carboxylate)
• 90950-43-9(methyl 2-(3-piperidyl)propanoate)